Rectal Cancer
SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)
- Details
ClinicalTrials.gov ID:
NCT05253651
Diagnosis Type:
NA
USOR Number:
- Address
,
P: